Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study). [PDF]
Pharmaceuticals (Basel)Chakraborty D +9 more
europepmc +1 more source
The Impact of Biosimilar Launch on Molecule Price and Pharmaceutical Expense: The Case of the Insulin Glargine in Italy [PDF]
Value in Health, 2017 A Tettamanti, L Cioni, C Tucci
openaire +1 more source
Advances in Biosimilars: A Systematic Review of Machine Learning Applications. [PDF]
Pharmaceuticals (Basel)Duarte V, Bas TG.
europepmc +1 more source
Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. [PDF]
Indian J OphthalmolChakraborty D, Sinha TK, Boral S, Das A.
europepmc +1 more source
A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007). [PDF]
Pharmaceuticals (Basel)Wang C +10 more
europepmc +1 more source
Peep into anti-vascular endothelial growth factor. [PDF]
Indian J OphthalmolVerma L, Singh S, Ramachandran O.
europepmc +1 more source
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis. [PDF]
United European Gastroenterol JHart A +15 more
europepmc +1 more source
Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products
IOSR Journal of Pharmacy (IOSRPHR), 2014 openaire +1 more source
Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. [PDF]
Int J Technol Assess Health CareHussain A, Fairbairn R, Khan SK.
europepmc +1 more source
Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. [PDF]
Adv TherYamauchi PS +4 more
europepmc +1 more source